SFX by Ex Libris Inc.

Title:	Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Source:	Science [0036-8075] Gorre, M E yr:2001

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Hochhaus, A. "Roots of clinical resistance to STI-571 cancer therapy." Science 293.5538 (2001): 2163-2163.
description	2.	Shah, Neil P P. "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia." Cancer cell 2.2 (2002): 117-25.
description	3.	Liu, Y. "Rational design of inhibitors that bind to inactive kinase conformations." Nature chemical biology 2.7 (2006): 358-364.
description	4.	Litzow, Mark R R. "Imatinib resistance: obstacles and opportunities." Archives of pathology & laboratory medicine 130.5 (2006): 669-679.
description	5.	Nyberg, Kara A A. "Toward maintaining the genome: DNA damage and replication checkpoints." Annual Review of Genetics 36.1 (2002): 617-56.
description	6.	Druker, Brian J J. "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia." The New England journal of medicine 355.23 (2007): 2408-17.
description	7.	Shah, C. "Overriding imatinib resistance with a novel ABL kinase inhibitor." Science 305.5682 (2004): 399-401.
description	8.	Nagar, B. "Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)." Cancer research 62.15 (2002): 4236-43.
description	9.	O'Hare, T. "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants." Cancer research 65.11 (2005): 4500-5.
description	10.	Daley, George Q Q. "Mechanisms and implications of imatinib resistance mutations in BCR-ABL." Current opinion in hematology 11.1 (2004): 35-43.
description	11.	Blyth, K. "The RUNX genes: gain or loss of function in cancer." Nature reviews. Cancer 5.5 (2005): 376-87.
description	12.	Bedi, A. "Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia." Blood 83.8 (1994): 2038-44.
description	13.	Travis, J. "Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance." Science 305.5682 (2004): 319-21.
description	14.	Okram, B. "A general strategy for creating "inactive-conformation" abl inhibitors." Chemistry & biology 13.7 (2006): 779-86.
description	15.	Dirks, Sheila K B. "Identification of human brain tumour initiating cells." Nature 432.7015 (2004): 396-401.
description	16.	Adrián, Francisco J J. "Allosteric inhibitors of Bcr-abl-dependent cell proliferation." Nature chemical biology 2.2 (2006): 95-102.
description	17.	Zhang, J. "Targeting cancer with small molecule kinase inhibitors." Nature reviews. Cancer 9.1 (2008): 28-39.
description	18.	Lietha, D. "Structural basis for the autoinhibition of focal adhesion kinase." Cell 129.6 (2007): 1177-87.
description	19.	Kim, B-R E. "Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR–ABL leukemic cells." Leukemia 27.8 (2013): 1650-1658.
description	20.	Cortes, J. "Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders." Cancer 100.10 (2004): 2064-78.